How much does a box of Erlotinib cost?

Erlotinib (Erlotinib) is a small molecule tyrosine kinase inhibitor targeting EGFR mutations. It is mainly used for the treatment of non-small cell lung cancer (NSCLC). In clinical application, it can be used for patients with advanced EGFR mutation-positive NSCLC who have not received systemic treatment before, and can also be used for maintenance or rescue treatment after chemotherapy failure. In addition, some studies and guidelines show that erlotinib also has exploratory applications in patients with specific cholangiocarcinoma or pancreatic cancer, but its main approved indications are still concentrated in EGFR-mutated lung cancer. By inhibiting the EGFR signaling pathway, erlotinib blocks tumor cell proliferation and metastasis and induces tumor cell apoptosis. It is a typical representative of precision medicine.

In the domestic market, erlotinib has been launched and included in medical insurance, and patients can purchase it directly at hospital pharmacies. The price of a single box varies according to specifications and regions, usually ranging from tens of yuan to six to seven hundred yuan. After medical insurance reimbursement, the patient's out-of-pocket payment ratio is further reduced. There are original drugs and generic drugs in foreign markets. The price of Indian generic drugs is about RMB 800, which is more economical than original drugs. At the same time, the drug ingredients are basically the same and the efficacy is equivalent. Due to the convenience of oral administration, patients only need to follow the doctor's instructions to regularly review blood routine, liver and kidney function and imaging evaluation when taking the medicine at home to ensure efficacy and safety.

Common side effects of erlotinib include rash, diarrhea, nail changes, etc. In severe cases, interstitial pneumonia or abnormal liver function may occur, so patients need to be closely followed up during the medication. Clinicians will develop a dosage plan based on the patient's specific EGFR mutation type, physical condition, and previous treatment history.

Generally speaking, erlotinib has high accessibility and moderate economic burden in China. At the same time, erlotinib is still the preferred targeted therapy drug for EGFR mutation-positive NSCLC patients, providing patients with precise and long-term manageable treatment options.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib